Surgical management of submacular hemorrhage due to n-AMD: a comparison of three surgical methods
Standard
Surgical management of submacular hemorrhage due to n-AMD: a comparison of three surgical methods. / Grohmann, Carsten; Dimopoulos, Spyridon; Bartz-Schmidt, Karl Ulrich; Schindler, Philipp; Katz, Toam; Spitzer, Martin S; Skevas, Christos.
in: INT J RETINA VITR, Jahrgang 6, 2020, S. 27.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Surgical management of submacular hemorrhage due to n-AMD: a comparison of three surgical methods
AU - Grohmann, Carsten
AU - Dimopoulos, Spyridon
AU - Bartz-Schmidt, Karl Ulrich
AU - Schindler, Philipp
AU - Katz, Toam
AU - Spitzer, Martin S
AU - Skevas, Christos
N1 - © The Author(s) 2020.
PY - 2020
Y1 - 2020
N2 - Background: To compare and assess the efficacy of three surgical methods for the treatment of acute submacular hemorrhage (ASH): pneumatic displacement with C2F6, in combination with intravitreal injection of bevacizumab and rtPA, pars plana vitrectomy (PPV) with intravitreal injection of gas (C2F6), bevacizumab and subretinal injection of recombinant tissue plasminogen activator (rtPA), pars plana vitrectomy (PPV) with intravitreal injection of gas (C2F6), bevacizumab and intravitreal injection of recombinant tissue plasminogen activator (rtPA).Methods: The study included 85 patients with ASH. In the group without PPV (A), patients were treated with intravitreal injection of C2F6, bevacizumab and rtPA. In the second and third group, patients underwent a PPV, intravitreal injection of bevacizumab, pneumatic displacement with C2F6 and a subretinal (B) or intravitreal (C) injection of recombinant tissue plasminogen activator (rt PA).Results: In group A, mean BCVA increased from preop logMAR 1.41 to 1.05, in group B from 1.46 to 1.28 and in group C from 1.63 to 1.33. In group A, CFT changed from 764 ± 340 μm at time point 0 to 246 ± 153 μm at time point 1, in group B from 987 ± 441 μm to 294 ± 166 μm and in group C from 642 ± 322 μm to 418 ± 364 μm. Patients had an average of 5 injections after surgery.Conclusion: Our study demonstrates that the three methods are equally effective in improving the morphology and the BCVA of patients with ASH.
AB - Background: To compare and assess the efficacy of three surgical methods for the treatment of acute submacular hemorrhage (ASH): pneumatic displacement with C2F6, in combination with intravitreal injection of bevacizumab and rtPA, pars plana vitrectomy (PPV) with intravitreal injection of gas (C2F6), bevacizumab and subretinal injection of recombinant tissue plasminogen activator (rtPA), pars plana vitrectomy (PPV) with intravitreal injection of gas (C2F6), bevacizumab and intravitreal injection of recombinant tissue plasminogen activator (rtPA).Methods: The study included 85 patients with ASH. In the group without PPV (A), patients were treated with intravitreal injection of C2F6, bevacizumab and rtPA. In the second and third group, patients underwent a PPV, intravitreal injection of bevacizumab, pneumatic displacement with C2F6 and a subretinal (B) or intravitreal (C) injection of recombinant tissue plasminogen activator (rt PA).Results: In group A, mean BCVA increased from preop logMAR 1.41 to 1.05, in group B from 1.46 to 1.28 and in group C from 1.63 to 1.33. In group A, CFT changed from 764 ± 340 μm at time point 0 to 246 ± 153 μm at time point 1, in group B from 987 ± 441 μm to 294 ± 166 μm and in group C from 642 ± 322 μm to 418 ± 364 μm. Patients had an average of 5 injections after surgery.Conclusion: Our study demonstrates that the three methods are equally effective in improving the morphology and the BCVA of patients with ASH.
U2 - 10.1186/s40942-020-00228-x
DO - 10.1186/s40942-020-00228-x
M3 - SCORING: Journal article
C2 - 32637155
VL - 6
SP - 27
JO - INT J RETINA VITR
JF - INT J RETINA VITR
SN - 2056-9920
ER -
